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Abstract
Background:Type 2 diabetes (DM2) and impaired glucose metabolism (IGM) are associated with an increased cardiovascular dis-
ease risk. Impaired endothelial synthesis of nitric oxide (NO) is an important feature of atherothrombosis and can be estimated from
endothelium-dependent flow-mediated dilation (FMD). It is controversial whether or not FMD is impaired in DM2 and IGM. We inves-
tigated this issue in a population-based setting.Methods and results:In the study population (n = 650; 246 with normal glucose metabolism
(NGM), 135 with IGM and 269 with DM2; mean age: 67.6 years), FMD and endothelium-independent nitroglycerine-mediated dilation
(NMD) were ultrasonically estimated from the brachial artery and expressed as the absolute change in diameter in mm. The increase in
diameter (mean± standard deviation) in NGM, IGM and DM2 was 0.19± 0.15, 0.19± 0.18 and 0.13± 0.17 for FMD and 0.45± 0.21,
0.43±0.24 and 0.45±0.25 for NMD. After adjustment for age, sex, baseline diameter and percentage increase in peak systolic velocity, DM2,
as compared to NGM, remained associated with impaired FMD (regression coefficientβ (95%CI)) as compared to NGM,−0.06 mm (−0.09
to −0.03). IGM was not associated with impaired FMD (β, 0.01 mm (−0.02 to 0.04)). Additional adjustment for conventional cardiovascular
risk factors did not alter these associations. Hyperglycemia or hyperinsulinemia explained 2% of the association between DM2 and FMD.
NMD was not associated with glucose tolerance.Conclusions:This study shows that DM2 is independently associated with impaired FMD.
Hyperglycemia and hyperinsulinemia contribute minimally to this association. Impaired FMD may therefore, in part, explain the increased
cardiovascular disease risk in DM2, whereas the normal FMD in IGM suggests that other forms of endothelial dysfunction are important in
explaining the increased cardiovascular disease risk in IGM.
© 2004 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Cardiovascular disease is the major cause of mortality in
type 2 diabetes (DM2)[1]. An increased cardiovascular dis-
ease risk is already apparent in impaired glucose metabolism
(IGM), i.e., impaired fasting glucose and (or) impaired
glucose tolerance[2], and cannot be fully explained by
conventional cardiovascular risk factors associated with de-
∗ Corresponding author. Tel.:+31-20-444-0629;
fax: +31-20-444-4313.
E-mail address:cda.stehouwer@vumc.nl (C.D.A. Stehouwer).
teriorating glucose tolerance, such as hypertension, obesity
and dyslipidemia[3].
It is currently hypothesized that DM2 and IGM are as-
sociated with impaired endothelial synthesis of nitric oxide
(NO), and that this may explain, at least in part, the increased
cardiovascular disease risk associated with these conditions
[4,5]. Indeed, endothelium-derived NO is an important
anti-atherosclerotic and anti-thrombotic mediator, and im-
paired availability of endothelium-derived NO is thought
to play an important role in both early and late stages of
atherothrombotic disease[6]. Endothelial synthesis of NO
can be estimated from vasodilation and (or) flow increase
0021-9150/$ – see front matter © 2004 Elsevier Ireland Ltd. All rights reserved.
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in response to stimuli such as acetylcholine, bradykinine
or increased shear stress, responses that are collectively
referred to as endothelium-dependent vasodilation.
Studies of endothelium-dependent vasodilation in DM2
and IGM have yielded contradictory results[7–28]. Both im-
paired[7–14,16,18,20–28]and normal[15,19]endothelium-
dependent vasodilation have been reported in DM2 and
impaired glucose tolerance, whereas some studies have re-
ported that both endothelium-dependent and -independent
responses are impaired in DM2, suggesting impaired func-
tion of vascular smooth muscle rather than the endothelium
[8,12,14,20,21,24]. These inconsistent results may have re-
sulted from selection, as these studies have been relatively
small and have not been population-based. In view of these
considerations, we investigated, in a population-based co-
hort, associations between DM2 and IGM, and impaired
endothelium-dependent or -independent vasodilation, as
measured by brachial artery ultrasonography.
2. Methods
2.1. Study population
For the present investigation, we used data from the 2000
Hoorn Study follow-up examination[29] and the Hoorn
Screening Study[30], both of which were population-based.
The exact sampling procedures have been described else-
where[29,30]. Briefly, the Hoorn Study is a study of glucose
metabolism in the general population (= 2484), which
started in 1989. In 2000, a follow-up examination was car-
ried out among all surviving participants. We invited all
those who had diabetes, as determined by an oral glucose
tolerance test, or who were treated for diabetes at the 1996
follow-up (n = 176). We also invited random samples of
individuals with normal glucose metabolism (NGM) (n =
705) and IGM, either impaired fasting glucose or impaired
glucose tolerance (n = 193). Of 1074 individuals thus in-
vited, 648 (60%) participated. Additionally, to increase the
number of individuals with DM2, we invited 217 individuals
from the Hoorn Screening Study[30], a screening study for
DM2 in the general population, 188 (87%) of whom partici-
pated. Data on 14 individuals were missing due to logistical
problems. The population (n = 822) was categorized ac-
cording to the WHO-1999 criteria[31], and thus consisted
of three groups: 290 with NGM, 187 with IGM, and 345
with DM2. The study was approved by the local ethics
committee. All participants gave their written informed
consent.
2.2. Non-participants
Among the 455 non-participants (53% women), 13% were
complete non-responders. The remaining non-participants
gave various reasons not to participate: lack of interest
(30%); co-morbidity (23%); age (7%); unwillingness to
travel (6%); participation too time-consuming (6%); and
miscellaneous reasons (15%).
2.3. General procedures
All individuals underwent the ultrasound examination ac-
cording to the guidelines of the International Brachial Artery
Reactivity Task Force[32].
The diameter of the right brachial artery (20 mm proximal
to the antecubital fossa) was assessed with the use of an ultra-
sound scanner equipped with an 7.5 MHz linear probe (350
series, Pie Medical, Maastricht, The Netherlands). The scan-
ner was connected to a PC equipped with vessel wall move-
ment detection software and an acquisition system (Wall
Track System, Pie Medical, Maastricht, The Netherlands).
This set-up enables measurement of diameter, as described
in detail elsewhere[33–35]. Blood flow (peak systolic veloc-
ity) was estimated by pulsed-wave Doppler from a sample
volume in the center of the artery at a 60◦ angle. To secure
the ultrasound image and measurement position through-
out the study, we used an stereotactic probe-holding device,
while the subject’s arm was positioned over a foam cast to
inhibit movement.
2.3.1. Determination of endothelium-dependent
flow-mediated dilation (FMD)
The measurement protocol has been described in detail
[36]. Briefly, baseline diameter (mean of three measure-
ments) and peak flow velocity (mean of two measure-
ments) were determined. A pressure cuff, placed on the
forearm, was then automatically inflated and kept con-
stant at supra-systolic pressure (brachial systolic pressure
+100 mmHg) in order to induce forearm ischemia. After
5 min the cuff was released, which was followed by an in-
crease in blood flow. This increase in blood flow increased
shear stress, which served as the stimulus for FMD. After
cuff release, maximum peak flow velocity was measured
within 15 s, and diameter at 45, 90, 180 and 300 s. The
maximum diameter in any of these four measurements was
used in the statistical analysis.
2.3.2. Determination of endothelium-independent
nitroglycerine-mediated dilation (NMD)
Next, 15 min of rest were taken to re-establish baseline
conditions. Baseline diameter (mean of three measurements)
and peak flow velocity (mean of two measurements) were
re-determined. Nitroglycerin (400g, Nitrolingual Spray,
Pohl-Boskamp, Germany) was then sublingually adminis-
tered; after 5 min, diameter (mean of three measurements)
and peak flow velocity (mean of two measurements) were
again determined.
2.4. Reproducibility
Reproducibility was assessed in ten individuals (five men;
58.2± 9.5 years) who were examined twice, 2 weeks apart.
R.M.A. Henry et al. / Atherosclerosis 174 (2004) 49–56 51
The intra-observer intersession coefficients of variation
[CV = (standard deviation of the mean difference/(√2 ×
pooled mean)] were 4.3% for diameter, 14.7% for FMD
and 10.3% for NMD (the latter two expressed as absolute
diameter change).
2.5. Other measurements
Health status, medical history, current medication use
and smoking habits were assessed by a questionnaire[29].
Glucose, glycated hemoglobin, insulin, creatinine, urinary
albumin, serum total, high-density and low-density lipopro-
tein cholesterol and triglycerides were determined as de-
scribed elsewhere[29,37]. Resting electrocardiograms were
automatically coded according to the Minnesota Code[38],
and body mass index and waist-to-hip ratio were calculated.
Brachial systolic and diastolic pressures were assessed
in the left upper arm at 5-min intervals with an oscillo-
metric device (Collin Press-Mate, BP-8800, Komaki-City,
Japan). Hypertension, prior cardiovascular disease and
(micro)-albuminuria were defined as described previously
[37,39].
2.6. Statistical analyses
All analyses were carried out with SPSS (SPSS, Chigaco,
USA). Trend analyses were carried out by one-way analy-
sis of variance. We used multiple linear regression analysis
to investigate the associations between glucose tolerance
and FMD. All associations were first analyzed without
Table 1
Characteristics of the study population according to glucose tolerance status
NGM IGM DM2 P (trend)
N (m/f) 246 (119/127) 135 (71/64) 269 (139/130) –
Age (years) 67.8± 5.6 69.1± 5.9 66.5± 8.1a 0.185
Systolic blood pressure (mmHg) 135± 19 143± 17b 148 ± 19a,b <0.001
Diastolic blood pressure (mmHg) 74± 9 78 ± 9b 79 ± 9b <0.001
Hypertension (%) 53 71b 81b <0.001
Antihypertensive medication (%) 22 30b 50b <0.001
Total cholesterol (mmol/l) 5.86± 1.01 5.92± 0.99 5.56± 1.07a,b 0.005
HDL cholesterol (mmol/l) 1.51± 0.41 1.43± 0.41 1.26± 0.35a,b <0.001
LDL cholesterol (mmol/l) 3.77± 0.88 3.78± 0.92 3.47± 0.93a,b 0.003
Triglycerides (mmol/l) 1.2 (0.9 – 1.6) 1.4 (1.0 – 1.9)b 1.6 (1.2–2.3)a,b <0.001
Lipid-lowering medication (%) 11 15 20b 0.039
Fasting glucose (mmol/l) 5.42± 0.37 6.05± 0.52b 7.61 ± 1.65a,b <0.001
Post-load glucose (mmol/l) 5.59± 1.12 7.99± 1.65b 11.57± 2.76a,b <0.001
Glycated hemoglobin (%) 5.86± 0.41 5.83± 0.39 6.57± 0.90a,b <0.001
Insulin (pmol/l) 46.0 (34.3–59.0) 66.0 (50.0–88.0)b 82.5 (55.0–109.8)a,b <0.001
Body mass index (kg/m2) 25.9 ± 3.2 27.3± 3.3b 28.5 ± 3.8a,b <0.001
Waist-to-hip ratio 0.89± 0.09 0.94± 0.08b 0.96 ± 0.10a,b <0.001
Current smoking (%) 16 16 12a,b 0.537
Serum creatinine (mol/l) 95 ± 14 95± 15 95± 19 0.847
(Micro-)albuminuria (%) 9 15 19b <0.001
Prior cardiovascular disease (%) 41 49 51b <0.001
Mean± standard deviation or median (inter-quartile range). NGM: normal glucose metabolism; IGM: impaired glucose metabolism; DM2: type 2 diabetes.
a P<0.05 as compared to IGM.
b As compared to NGMP < 0.05. P for trend tested by ANOVA.
any adjustments and then with adjustment for potential
confounders. In the adjusted models, age, sex, baseline di-
ameter and the increase in shear stress (estimated from the
percentage increase in peak systolic velocity) were consid-
ered first[40,41]. We used an interaction term to investigate
whether the association between FMD and glucose toler-
ance differed according to sex[26]. P-values<0.05 were
considered statistically significant, except for interaction
analyses, where we usedP < 0.10.
3. Results
3.1. Ultrasonography
Of the 822 participants, qualitatively satisfactory ultra-
sound examinations were obtained in 650 individuals. Data
were missing for logistical reasons (n = 18); technical rea-
sons (n = 8); and poor definition of the arterial wall (n =
107) due to obesity (n = 85 (23 with NGM, 26 with IGM and
36 with DM2; body mass index 30.4, 30.7 and 32.7 kg/m2,
respectively), body mass index of those with qualitatively
satisfactory ultrasound examination versus those without,
26.8 ± 3.2 kg/m2 versus 31.1 ± 5.4 kg/m2, P < 0.001) or
the inability to remain motionless due to musculoskeletal
disorders (n = 39).
3.2. Baseline characteristics
Table 1shows the characteristics of the study populat-
ion.
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Table 2
Right brachial artery variables according to glucose tolerance
NGM IGM DM2
Diameter (mm)
Baseline 4.55± 0.76 (2.87 to 7.07) 4.67± 0.72 (2.84 to 7.60) 4.78± 0.74 (2.94 to 7.22)a,b
After FMD 4.74 ± 0.75 (3.09 to 7.14) 4.86± 0.73 (3.09 to 7.67) 4.91± 0.73 (2.87 to 7.38)a,b
After NMD 4.99 ± 0.77 (3.17 to 7.27) 5.09± 0.72 (3.27 to 7.70) 5.22± 0.72 (3.37 to 7.50)a,b
Absolute change in diameter (mm)
After FMD 0.19 ± 0.15 (−0.11 to 1.02) 0.19± 0.18 (−0.02 to 0.93) 0.13± 0.17 (−1.24 to 0.69)a,b
After NMD 0.45 ± 0.21 (0.00 to 1.42) 0.43± 0.24 (−0.81 to 1.21) 0.45± 0.25 (−1.00 to 1.36)
Percentage change in diameter (%)
After FMD 4.47 ± 3.78 (−1.82 to 29.50) 4.23± 3.92 (−0.43 to 19.15) 2.96± 3.66 (−22.93 to 16.64)a,b
After NMD 10.29 ± 5.49 (−0.05 to 41.74) 9.64± 5.48 (−14.32 to 29.63) 9.88± 6.75 (−18.55 to 40.10)
Peak systolic velocity (cm/s)
Baseline 56± 13 (31 to 114) 58± 13 (26 to 97) 60± 14 (32 to 115)a,b
After reactive hyperemia 108± 29 (52 to 217) 105± 22 (51 to 175) 105± 25 (56 to 195)
% increase 95± 49 (4 to 383) 84± 37 (4 to 221)a 77 ± 38 (4 to 188)a,b
Results are expressed as mean± standard deviation (range). FMD and NMD, respectively stand for flow-mediated dilation and nitroglycerine-mediated
dilation.
a P ≤ 0.01 as compared to NGM.
b P ≤ 0.03 as compared to IGM; otherP-values were≥0.12.
3.3. FMD and NMD
Individuals with impaired fasting glucose (n = 48) and
impaired glucose tolerance (n = 87) did not significantly
differ from each other with regard to FMD (P = 0.42),
NMD (P = 0.29) or other cardiovascular risk factors and
were therefore combined in the analyses.
Baseline diameter increased with deteriorating glucose
tolerance, and percentage increase in peak systolic ve-
locity decreased (Table 2). After adjustment for age, sex,
baseline diameter and percentage increase in peak sys-
tolic velocity, DM2, as compared to NGM, was associated
with smaller FMD, but IGM was not (Table 3, model
2). Further adjustment for potential confounders did not
materially affect these estimates (Table 3, models 3–8),
even though, as expected, the presence of cardiovascular
risk factors in general was associated with smaller FMD
(Table 4).
NMD was not associated with glucose tolerance in unad-
justed (Table 2, Fig. 1) or adjusted analyses (data not shown).
Table 3
Flow-mediated dilation according to glucose tolerance: adjusted analyses
Model Added variables IGM DM2
1 – −0.001 (−0.04 to 0.04) −0.06 (−0.09 to−0.03)
2 Age, sex, baseline diameter, flow increase 0.01 (−0.02 to 0.04) −0.06 (−0.09 to−0.03)
3 Model 2+ prior cardiovascular disease 0.02 (−0.02 to 0.05) −0.05 (−0.08 to−0.02)
4 Model 2+ hypertension 0.01 (−0.02 to 0.05) −0.05 (−0.08 to−0.02)
5 Model 2+ lipid-lowering medication 0.01 (−0.02 to 0.05) −0.05 (−0.08 to−0.03)
6 Model 2+ body mass index 0.01 (−0.03 to 0.04) −0.06 (−0.09 to−0.03)
7 Model 2+ (micro-)albuminuria 0.01 (−0.02 to 0.05) −0.05 (−0.08 to−0.03)
8 Model 2+ smoking 0.01 (−0.02 to 0.04) −0.06 (−0.09 to−0.03)
Results are expressed as betas and 95% confidence intervals, with NGM as reference category. The absolute change in diameter, in millimeters, was the
dependent variable. Similar results were obtained when model 2 was additionally adjusted for systolic or diastolic pressure, lipid profile, waist-to-hip
ratio, or serum creatinine (data not shown).
3.4. Additional analyses
The association between FMD and glucose tolerance did
not differ according to sex (P(interaction) = 0.47). Our results
were not materially altered if we simultaneously added all
variables from model 1–8 into one statistical model (data
not shown). Our results were also not materially altered
if we compared those who were examined in the morning
(08:00 h, completely fasting) to those examined in the after-
noon (12:00 h, provided with a light breakfast at 08:00 h).
The percentages of fasted/non-fasted individuals did not sta-
tistically significantly differ between NGM, IGM and DM2
(data not shown).
To estimate the contribution of hyperglycemia and of hy-
perinsulinemia to the smaller FMD associated with DM2,
we compared the above analyses with those adjusted for
HbA1c (n = 269) (or fasting glucose (n = 269) or post-load
glucose (n = 222, as 47 individuals with previously di-
agnosed DM2 did not undergo the oral glucose tolerance
test) and for fasting insulin concentrations (n = 259, as 10
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Table 4
Cross-sectional associations between flow-mediated dilation and cardio-




Age 6.9 years −0.033 <0.001




Fasting glucose 1.5 mmol/l −0.020 0.002
Post-load glucose 2.6 mmol/l −0.011 0.165
Glycated hemoglobin 0.8% −0.019 0.005
Insulin 51 pmol/l −0.013 0.061
Systolic pressure 19 mmHg −0.029 <0.001
Diastolic pressure 9 mmHg −0.024 <0.001
Hypertension Yes vs. no −0.024 <0.001
Antihypertensive
medication
Yes vs. no −0.027 <0.001
Total cholesterol 1.0 mmol/l −0.005 0.489
High-density lipoprotein
cholesterol
0.40 mmol/l 0.006 0.360
Low-density lipoprotein
cholesterol
0.9 mmol/l 0.009 0.189
Triglycerides 0.9 mmol/l −0.014 0.029
Lipid-lowering
medication
Yes vs. no −0.013 0.049
Body mass index 3.6 kg/m2 −0.016 0.018
Waist-to-hip ratio 0.09 −0.010 0.133
Serum creatinine 16mol/l 0.012 0.078
(Micro-)albuminuria Yes vs. no −0.017 0.011
Smoking Yes vs. no −0.020 <0.001
Prior cardiovascular
disease
Yes vs. no −0.020 0.004
The regression coefficients are expressed as standardizedβ (in mm) per
change of 1 standard deviation of the independent variable to facilitate
direct comparison.
individuals were on insulin therapy). These adjustments ex-
plained at most 2% of the observed associations (data not
shown). Conversely, the associations between either fasting
glucose, HbA1c or insulin on the one hand and FMD on
Fig. 1. Absolute change in diameter (mm) for flow-mediated dilation
(FMD) and nitroglycerine-mediated dilation (NMD) according to glucose
tolerance.
the other (Table 4) were entirely accounted for by DM2 in a
model adjusted for sex, age, baseline diameter and increase
in peak systolic velocity (data not shown).
4. Discussion
This population-based study of glucose tolerance and
FMD had three main findings. First, after adjustment for
age, sex, baseline diameter and increase in peak systolic
velocity, DM2, as compared to NGM, was associated with
smaller FMD, whereas IGM was not. These findings were
independent of other cardiovascular risk factors. Second,
the smaller FMD response in DM2 is likely to be caused
by impaired endothelial rather than smooth muscle cell
function, as the NMD response was not impaired. Third, in-
dices of hyperglycemia and hyperinsulinemia explained at
most 2% of the association between DM2 and FMD. Taken
together, our data support the hypothesis that impaired en-
dothelial synthesis of NO may explain, at least partially, the
increased cardiovascular disease risk in DM2, but does not
support the existence of a similar mechanism in IGM.
Our investigation had important advantages over previous
studies, which were relatively small and concerned selected
populations. Additionally, to be able to adjust for potential
confounders, we extensively characterized our population in
terms of cardiovascular disease and risk factors.
The present and previous data suggest that impaired en-
dothelial function in DM2 is a generalized phenomenon,
which is neither restricted to the specific stimulus applied
[11,14,23,27]nor to vascular territory[13,26,27], the type of
vascular bed[9,16,27]or the type of endothelial dysfunction
[42,43]. Surprisingly, the impaired FMD in DM2 could only
be explained to a minor extent by indices of hyperglycemia
or hyperinsulinemia. In contrast, some studies suggest that
acutehyperglycemia and hyperinsulinemia may acutely im-
pair FMD [44–46], although the data are not consistent[47]
and may differ along the arterial tree[48]. Taken together,
these[44–47]and the present data suggest that the effects of
acute hyperglycemia and hyperinsulinemia may differ from
those of more chronically elevated glucose and insulin lev-
els. Indeed, there is evidence that endothelial cells can adapt
to hyperglycemia[49,50]. Our results thus raise the possibil-
ity that other pathophysiological mechanisms are involved,
such as chronic low-grade inflammation and increased ox-
idative and carbonyl stress[43,51]. Interestingly, Tan et al.
[8] have recently shown that increased concentrations of ad-
vanced glycation end products were independently associ-
ated with impaired endothelium-dependent vasodilation.
Somewhat surprisingly, IGM was not associated with im-
paired FMD, although the confidence intervals inTable 3do
not entirely exclude impaired FMD in IGM. In addition, it is
important to note that impaired brachial artery FMD denotes
endothelial dysfunction with regard to a particular function
(vasomotor regulation), a particular vascular bed (conduit
artery), and a particular stimulus (shear stress). Normal FMD
54 R.M.A. Henry et al. / Atherosclerosis 174 (2004) 49–56
in IGM therefore does not imply that endothelial function
in IGM is normal in general. In fact, there is considerable
evidence that it is not[52,53]. Our findings in the present
population are, however, in concordance with the observa-
tion that hyperglycemia and hyperinsulinemia were of lim-
ited value in explaining the association between FMD and
DM2. These data also argue against the hypothesis that im-
paired FMD is an important mechanism linking IGM with
increased cardiovascular disease risk. In contrast, we have
recently shown that, like DM2, IGM is associated with in-
creased arterial stiffness and arterial remodeling[35,54,55],
suggesting that these processes may be important early de-
terminants of cardiovascular disease risk in IGM, while im-
paired FMD may occur later.
Our study had several limitations. First, the method we
employed to estimate FMD assumes that FMD is mostly
or entirely NO-dependent, that exogenous administration
of glyceryltrinitrate adequately mimics the effects of en-
dogenous release of NO, and that there is no rightward
shift of the glyceryltrinitrate dose–response relationship of
vascular smooth muscle cells[56,57]. The validity of these
assumptions remains to be established. Nevertheless, there
is increasing evidence that impaired endothelium-dependent
vasodilation, including impaired flow-mediated vasodila-
tion, is associated with an adverse cardiovascular prognosis
[58,59]. Secondly, we observed that ischemia-induced re-
active hyperemia (i.e., the increase in flow and thus shear
stress), expressed as percentage increase in peak systolic
velocity, decreased with deteriorating glucose tolerance
(Table 2). As age and hypertension were also negatively as-
sociated with the increase in peak systolic velocity (details
not shown), and as age and hypertension are associated with
microvascular rarefaction[17], the finding of decreased
peak systolic velocity in IGM and diabetes may have been
related to arteriolar and capillary rarefaction[17,27,60],
which would decrease ischemia-induced microvascular
dilatation and, consequently, the pressure drop over the
brachial artery and the amount of reactive hyperemia. As a
result, the increase in shear stress was slightly less in IGM
and DM2 than in NGM. This issue, however, did not affect
our results, as the differences were small and were adjusted
for in the analyses. Thirdly, our findings were obtained in
an elderly population characterized by the concurrence of
several cardiovascular disease risk factors. Therefore, infer-
ences to other populations (e.g., younger and(or) with less
cardiovascular disease risk factors) should be made with
care. Finally, individuals with a high body mass index were
less likely to participate, which may have resulted in an
underestimation of the confounding role of body mass in-
dex. We consider this unlikely, however, as adjustment for
body mass index had no effect whatsoever on the associa-
tion between FMD and glucose tolerance (Table 3), despite
the clear association between FMD and body mass index
(Table 4).
In conclusion, we have shown that DM2 is associated with
impaired FMD, whereas IGM is not. The mechanism behind
this association is unclear but does not appear to involve
conventional cardiovascular risk factors, hyperglycemia or
hyperinsulinemia. Impaired endothelial synthesis of NO may
explain, at least partly, the increased cardiovascular disease
risk seen in DM2.
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